Pacira biosciences, inc. (PCRX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Operating activities:
Net income (loss)

-86

-11,016

2,157

7,604

7,438

-471

-4,161

-11,118

-33,425

-42,611

-51,178

-65,746

-53,961

-37,949

-36,475

-11,224

-3,258

1,856

-9,362

-15,452

-20,497

-33,234

-31,474

-43,254

-52,248

-63,909

-68,299

-69,260

-63,525

-52,281

-51,218

-44,981

-45,447

-43,328

0

0

0

Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation of fixed assets and amortization of intangible assets

20,797

19,576

18,537

16,436

14,003

13,165

12,773

12,630

13,491

13,833

13,434

13,351

12,858

12,919

12,778

12,330

11,897

11,475

18,391

17,953

17,503

17,363

9,028

7,966

6,919

5,747

5,493

5,580

5,699

5,648

5,486

5,098

4,704

4,314

0

0

0

Amortization of debt issuance costs

1,726

1,707

1,677

1,648

1,619

1,590

1,550

1,510

1,471

1,248

1,004

763

527

479

479

480

479

481

848

850

852

852

487

486

487

459

276

93

-89

-239

-234

-222

-169

-85

0

0

0

Amortization of debt discount

13,995

13,746

13,503

13,265

13,031

12,799

12,570

12,344

12,125

10,423

8,387

6,406

4,477

4,088

4,088

4,088

4,089

4,102

7,219

7,232

7,243

7,243

4,139

4,138

4,139

3,959

3,184

2,411

1,583

831

675

663

554

1,644

0

0

0

Loss on disposal and impairment of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Gain (Loss) on Extinguishment of Debt

-

-

-

-

-

-

-

-

-

-3,732

-3,732

-3,732

-3,721

0

0

0

0

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on disposal and impairment of fixed assets

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Stock-based compensation

35,063

33,650

32,647

31,510

30,774

31,725

31,733

32,289

32,586

31,601

31,139

29,837

30,158

31,248

33,244

34,710

34,341

33,368

48,462

47,322

45,563

42,021

20,485

16,575

13,263

11,513

9,783

7,475

6,289

4,776

3,748

2,721

2,233

2,493

0

0

0

Changes in contingent consideration

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on investment

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,509

-1,633

-1,972

196

72

-146

1,170

0

110

184

-849

0

224

105

-221

1

-14

0

0

0

Accounts receivable, net

-1,784

8,524

7,301

4,500

8,563

5,999

6,902

7,831

3,158

1,721

256

-1,184

1,801

4,082

846

4,370

1,390

3,489

11,329

9,663

14,469

13,703

10,746

12,790

10,726

10,238

7,312

4,541

4,383

2,239

963

2,159

-950

922

0

0

0

Inventories, net

10,936

8,026

13,651

9,034

6,985

7,157

5,772

8,451

9,732

10,133

1,636

-27,314

-33,433

-30,367

-18,656

12,147

27,480

32,382

40,575

37,680

29,005

21,811

8,056

4,973

4,604

3,480

3,700

4,922

5,682

10,832

10,239

7,415

3,300

-360

0

0

0

Prepaid expenses and other assets

5,915

3,885

4,267

4,493

3,662

3,228

1,670

-1,729

785

-3,476

-4,559

1,620

-2,591

3,377

5,562

2,947

5,296

2,007

2,268

953

2,182

2,317

1,030

593

-133

972

536

1,200

1,293

59

-139

-481

-95

608

0

0

0

Accounts payable, accrued expenses and income taxes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,175

-1,874

8,418

8,966

16,449

21,865

20,761

24,909

12,761

11,588

7,929

9,622

958

5,902

2,161

1,386

8,701

1,216

1,108

2,549

0

0

0

Royalty interest obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

276

1,246

1,510

1,706

1,611

739

606

511

434

374

959

1,087

1,076

1,418

1,245

1,832

1,815

0

0

0

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,426

-

5,644

5,644

13,679

13,783

7,327

7,440

-481

-472

-1,546

-4,781

-10,855

-16,778

-14,692

-11,885

-6,101

1,065

0

0

0

Accounts payable

2,488

-1,822

1,656

932

-2,121

-573

1,414

737

4,574

5,712

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and income taxes payable

679

20,213

9,278

9,350

7,660

5,203

1,932

-7,058

-1,676

3,647

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-7,848

-6,726

-737

327

955

897

256

-1,750

-2,398

-3,555

-4,453

-4,864

-2,186

-1,339

3,485

6,367

3,912

4,360

3,516

3,443

4,419

4,668

2,454

1,778

875

1,047

712

468

347

-106

-778

-711

-644

27

0

0

0

Payment of contingent consideration to MyoScience, Inc. securityholders

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by operating activities

73,229

70,520

65,836

64,111

55,058

48,870

44,581

25,144

15,090

17,785

18,203

32,695

36,580

33,453

33,098

26,133

25,770

28,021

37,591

41,232

42,272

38,406

4,940

-13,257

-34,785

-43,838

-58,115

-59,455

-66,374

-70,130

-56,547

-53,864

-44,558

-31,000

0

0

0

Investing activities:
Purchases of fixed assets

14,865

10,159

7,905

10,766

11,348

14,514

17,347

18,313

20,834

19,266

19,072

17,559

21,272

24,709

28,910

36,510

39,474

40,295

54,196

47,020

41,211

37,145

16,965

17,331

13,048

12,172

14,100

15,662

18,288

18,257

16,008

11,399

8,236

6,167

0

0

0

Purchases of investments

368,406

318,484

400,596

322,466

255,363

363,255

249,485

410,710

452,990

502,752

470,442

345,816

305,314

192,815

222,275

217,951

206,988

189,082

289,500

344,642

335,704

304,713

152,595

80,071

61,460

114,299

0

0

0

-

-

-

-

-

-

-

-

Sales of investments

267,049

319,468

307,951

323,643

380,611

405,188

443,353

483,493

407,263

321,713

258,419

154,344

158,916

171,627

219,426

219,126

212,534

217,240

215,270

189,540

175,161

148,302

99,016

111,705

99,586

85,564

81,734

63,920

71,499

53,120

0

0

0

-

-

-

-

Payment of contingent consideration

-

-

-

-

-

6,843

9,083

8,969

8,661

8,460

8,286

16,192

16,045

15,857

15,782

7,628

7,403

7,119

18,560

26,323

25,774

25,153

12,510

3,541

2,746

2,031

0

0

0

-

-

-

-

-

-

-

-

Proceeds from follow-on public offering, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) provided by investing activities

-235,535

-128,488

-220,856

-132,022

109,350

20,576

152,438

30,501

-90,222

-223,765

-239,381

-225,223

-183,715

-61,754

-47,541

-42,963

-41,331

-19,256

-146,986

-239,429

-251,993

-243,174

-107,519

-2,719

22,332

-42,938

-35,800

-41,224

-83,243

-29,522

-63,649

-64,405

-37,821

-36,123

0

0

0

Financing activities:
Proceeds from exercises of stock options

10,823

8,469

7,687

9,246

7,852

7,170

5,948

5,657

6,345

6,778

5,874

3,952

3,581

5,770

6,475

7,529

9,067

10,073

16,037

16,595

15,054

12,971

6,545

5,143

4,943

3,856

3,280

2,551

1,594

870

0

0

0

-

-

0

0

Proceeds from shares issued under employee stock purchase plan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from initial public offering, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

38,016

0

0

0

Proceeds from issuance of 2022 convertible senior notes

-

-

-

-

-

-

-

-

-

345,000

345,000

345,000

345,000

0

0

0

0

-

-

-

-

-

-

-

-

120,000

0

0

0

-

-

-

-

-

-

-

-

Repayment of 2019 convertible senior notes

0

338

0

0

0

-

0

2

481

118,193

118,193

118,191

117,716

4

0

0

0

-

-

-

-

-

-

-

-

27,500

27,500

27,500

53,065

26,250

0

0

0

-

-

-

-

Payment of debt issuance and financing costs

-

-

-

-

-

-

-

-

-

11,000

11,000

11,000

11,000

0

0

0

0

-

-

-

-

-

-

-

-

7,191

7,191

7,191

8,208

1,365

0

0

0

-

-

-

-

Conversion premium on 2019 convertible senior notes

-233

0

233

233

233

0

0

1

1

285

285

284

284

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of contingent consideration to MyoScience, Inc securityholders

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) provided by financing activities

1,859

3,670

9,218

10,777

9,065

8,954

7,706

7,412

7,725

224,162

222,952

221,033

221,076

7,261

8,363

9,417

9,693

10,699

127,402

127,960

237,097

235,014

116,952

115,550

4,943

89,165

88,589

87,860

150,676

63,610

112,503

112,264

48,261

87,158

0

0

0

Net (decrease) increase in cash and cash equivalents

-160,447

-54,298

-145,802

-57,134

173,473

78,400

204,725

63,057

-67,407

18,182

1,774

28,505

73,941

-21,040

-6,080

-7,413

-5,868

19,464

18,007

-70,237

27,376

30,246

14,373

99,574

-7,510

2,389

-5,326

-12,819

1,059

-36,042

-7,693

-6,005

-34,118

20,035

0

0

0

Supplemental cash flow information:
Cash paid for interest

8,194

8,199

8,199

8,205

4,108

8,205

4,108

8,614

8,618

6,896

6,896

4,310

4,306

3,852

3,852

3,853

3,853

4,224

9,417

9,780

10,112

10,066

5,216

5,237

5,167

3,500

4,096

2,793

3,645

4,229

4,456

4,661

4,732

4,739

0

0

0

Cash paid for income taxes, net of refunds

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

34

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Initial public offering costs paid in 2010

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

907

0

0

0

Non-cash investing and financing activities:
Issuance of common stock from conversion of 2019 convertible senior notes

-

-

-

-

-

-

-

-

-

126,328

120,960

120,960

120,466

0

0

0

0

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income Taxes Paid, Net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash investing and financing activities:
Retirement of equity component of 2019 convertible senior notes

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equity component of the 2022 convertible senior notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Net decrease in accrued fixed assets

511

125

-1,891

2,616

-294

-98

5,373

2,451

3,601

2,189

-4,028

-3,745

-3,522

-789

-1,017

-2,095

1,584

1,393

1,500

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of notes to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

51,222

0

0

0

Conversion of preferred stock to common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

0

0

0